Moderate-to-Severe Atopic Dermatitis
Pipeline by Development Stage
Drug Modality Breakdown
Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.
Key Trends
- JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
- Multiple patent cliffs emerging 2026-2028, creating generic competition risk
- Robust pipeline with 4,996 trials signals continued innovation and market expansion
Career Verdict
Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MOUNJARO (TIRZEPATIDE) | Eli Lilly and Company | $2.4B | 16% | PEAK | Growing | 15.7yr |
| 2 | SYMBICORT (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE) | AstraZeneca | $2.0B | 13% | LOE_APPROACHING | Stable | |
| 3 | JAKAFI (RUXOLITINIB) | Incyte | $1.9B | 13% | LOE_APPROACHING | Declining | 2.6yr |
| 4 | RESTASIS (CYCLOSPORINE) | AbbVie | $1.5B | 10% | PEAK | Stable | 8.0yr |
| 5 | RINVOQ (UPADACITINIB) | AbbVie | $976M | 7% | PEAK | Growing | 11.8yr |
Drug Class Breakdown
dominant class with patent cliff risk
established, mature market segment
driven by single blockbuster
established immunosuppression class
legacy biologic class with competition
Career Outlook
GrowingImmunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.
Breaking In
Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.
For Experienced Professionals
Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.
In-Demand Skills
Best For
Hiring Landscape
Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.
Top Hiring Companies
By Department
Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.
Competitive Landscape
7 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 17,825 patients across 50 trials
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Dupilumab in the Treatment of Keloids
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
Dupilumab in Chinese Adult Participants With CRSwNP
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The Study of CM310 in Patients With Atopic Dermatitis
Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
Dupilumab in Severe Chronic Hand Eczema
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
Related Jobs in Immunology
Director, Bioanalytical / Biomarkers
Senior Director, Regulatory Affairs Strategy
Associate Director, Pharmacovigilance
Regional Business Director, (West Region), Immunology
Regional Business Director, (Southeast Region), Immunology
Regional Business Director, (South Central Region), Immunology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.